News

Filter

1 to 9 of 18 results

Helsinn signs exclusive agreement with Mundipharma for distribution of anamorelin

Helsinn signs exclusive agreement with Mundipharma for distribution of anamorelin

11-02-2015

Swiss oncology specialist Helsinn has signed an exclusive agreement with Mundipharma to distribute and…

anamorelinGastro-intestinalsHelsinnLicensingMarkets & MarketingMundipharmaOncologyPharmaceutical

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Roche highlights late-stage pipeline beyond cancer

02-10-2013

Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…

Gastro-intestinalsKadcylalampalizumabOncologyOphthalmicsPharmaceuticalResearchRoche

Helsinn and Zealand to advance elsiglutide for chemotherapy-induced diarrhea prevention

28-05-2013

Privately-held Swiss pharmaceutical group Helsinn and its partner, Denmark-based Zealand Pharma A/S (Nasdaq:…

elsiglutideGastro-intestinalsHelsinnOncologyPharmaceuticalResearchZealand Pharma

Lexicon Pharma updates on clinical pipeline

21-02-2013

US drug developer Lexicon Pharmaceutical (Nasdaq: LXRX) yesterday updated its drug development pipeline,…

BiotechnologyDiabetesGastro-intestinalsLexicon PharmaceuticalsLX1032LX1033LX4211OncologyResearchtelotristat etiprate

Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended

17-02-2013

AbbVie (NYSE: ABBV), the new spin-out from Abbott Laboratories, has announced the first long-term, patient-reported…

Abbott LaboratoriesAbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraOncologyPharmaceuticalResearch

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top